




Figure S1: TEM photomicrographs of G*rVSV Δ G-HeV-G. **a)** Negative stained virion immunostained for HeV (G) with antibody conjugated to 10 nm gold nanoparticles (arrows). **b)** negative stained TEM photomicrograph of two G*rVSV Δ G-HeV-G particles depicting classical bullet-shaped VSV virion morphology.

Supplementary Table 1: Clinical signs of HeV or NiV infection in control hamsters vaccinated with rVSVΔG-GFP.

challenge virus	subject	survival/death	clinical disease
Hendra-Redlands	H4-1	6	rough coat (d5); recumbency (d6); seizure (d6); oronasal serosanguineous exudate (d6).
	H4-2	5	circling cage (d4); head-tilt (d4).
	H4-3	5	hunched posture (d5); rough coat (d4); oronasal serosanguineous exudate (d5).
	H4-4	5	hunched posture (d5); ataxia (d5).
	H4-5	5	hunched posture (d5); aggression (d5); hypersalivation (d4,5); head-tilt (d5); imbalance (d5); oronasal serosanguineous exudate (d5).
	H4-6	5	hypersalivation (d5); aggression (d5); head-tilt (d5); imbalance (d5)
	H4-7	5	hunched posture (d5); hypersalivation (d5); imbalance (d5).
	H4-8	5	hunched posture (d5); hypersalivation (d5); imbalance (d5).
	H4-9	5	hypersalivation (d5); head-tilt (d5); imbalance (d5);
	H4-10	5	hypersalivation (d5); imbalance (d5).
	H4-11	5	orbital tightening (d5); head-tilt (d5).
	H4-12	5	hunched posture (d4); orbital tightening (d4).
Nipah-Bangladesh	H5-1	28	none.
	H5-2	15	head-tilt (d15); orbital tightening (d15); hunched posture (d15); imbalance (d15).
	H5-3	9	hyperventilation (d9); orbital tightening (d9).
	H5-4	7	orbital tightening (d6); rough coat (d6); hunched posture (d6).
	H5-5	28	none.
	H5-6	9	paralysis (d9).
	H5-7	28	none.
	H5-8	15	orbital tightening (d15); ataxia (d15); paralysis (d15); oronasal serosanguineous exudate (d15).
	H5-9	6	hypothermia (d6); ataxia (d6); hyperventilation (d6).
	H5-10	7	rough coat (d7); orbital tightening (d7); hyperventilation (d7).
	H5-11	8	paralysis (d8).
	H5-12	8	hyperventilation (d8); orbital tightening (d8).

Supplementary Table 2: Clinical signs of HeV or NiV infection in hamsters treated with anti-rVSV-HeV or anti-rVSV-GFP antiserum

challenge virus	treatment	subject	survival/death	clinical disease
Hendra-Redlands	anti-rVSV-HeV	H1-1	12	ataxia (d11); dyspnea (d12); paralysis (d12).
		H1-2	15	no overt disease noted, possible subclinical disease
		H1-3	9	dyspnea (d9); ataxia (d9); imbalance (d9).
		H1-4	28	none.
		H1-5	28	none.
		H1-6	28	none.
		H1-7	28	none.
		H1-8	28	none.
	anti-rVSV-GFP	H2-1	5	rough coat (d4); no other overt disease noted, possible subclinical disease
		H2-2	5	no overt disease noted, possible subclinical disease
		H2-3	5	rough coat (d4).
		H2-4	4	rough coat (d4); hypersalivation (d4); head-tilt (d4), ataxia (d4), paralysis (d4).
		H2-5	6	hypersalivation (d6); paralysis (d6); ataxia (d6).
		H2-6	4	rough coat (d4); orbital tightening (d4); imbalance (d4); ataxia (d4); seizure (d4).
		H2-7	5	rough coat (d5); hypersalivation (d5); imbalance (d5); ataxia (d5); muscle spasms (d5).
		H2-8	4	rough coat (d4); orbital tightening (d4); hypersalivation (d4); imbalance (d4); ataxia (d4); oronasal serosanguineous exudate (d4).
Nipah-Bangladesh	anti-rVSV-HeV	H3-1	8	ataxia (d8); dyspnea (d8); oronasal serosanguineous exudate (d8); hemiparesis (d8).
		H3-2	28	none.
		H3-3	28	none.
		H3-4	28	none.
		H3-5	28	none.
		H3-6	9	rough coat (d9); orbital tightening (d9); dyspnea (d9).
		H3-7	28	none.
		H3-8	28	none.
	anti-rVSV-HeV	H4-1	7	rough coat (d7); orbital tightening (d7); ataxia (d7); dyspnea (d7).
		H4-2	7	rough coat (d7); orbital tightening (d7); ataxia (d7); paralysis (d7).
		H4-3	28	none.
		H4-4	7	none.
		H4-5	7	none.
		H4-6	8	rough coat (d6,7,8); orbital tightening (d7,8); recumbency (d8); hypersalivation (d8); seizure (d8).
		H4-7	8	rough coat (d6); paralysis (d8); ataxia (d8);
		H4-8	10	rough coat (d6,7,8,9,10); orbital tightening (d10); paralysis (d10).